Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.
Breast Neoplasms
/ economics
Budgets
Cancer Survivors
/ psychology
Cognitive Behavioral Therapy
/ economics
Cost-Benefit Analysis
Female
Health Expenditures
Hot Flashes
/ therapy
Humans
Hyperhidrosis
/ therapy
Internet
Menopause, Premature
/ physiology
Netherlands
Quality-Adjusted Life Years
Waiting Lists
Breast cancer
Budget impact
Cognitive behavioral therapy
Cost-effectiveness
Internet-based
Menopause
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
15
06
2019
accepted:
13
08
2019
pubmed:
28
8
2019
medline:
21
3
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Internet-based cognitive behavioral therapy (iCBT), with and without therapist support, is effective in reducing treatment-induced menopausal symptoms and perceived impact of hot flushes and night sweats (HF/NS) in breast cancer survivors. The aim of the current study was to evaluate the cost-utility, cost-effectiveness, and budget impact of both iCBT formats compared to a waiting list control group from the Dutch healthcare perspective. A Markov model was constructed with a 5-year time horizon. Costs and health outcomes were measured alongside a randomized controlled clinical trial and included quality-adjusted life years (QALYs), overall levels of menopausal symptoms, and perceived impact of HF/NS. Uncertainty was examined using probabilistic and deterministic sensitivity analyses, together with a scenario analysis incorporating a different perspective. iCBT was slightly more expensive than the waiting list control, but also more effective, resulting in incremental cost-utility ratios of €23,331/QALY and €11,277/QALY for the guided and self-managed formats, respectively. A significant reduction in overall levels of menopausal symptoms or perceived impact of HF/NS resulted in incremental costs between €1460 and €1525 for the guided and €500-€753 for the self-managed format. The estimated annual budget impact for the Netherlands was €192,990 for the guided and €74,592 for the self-managed format. Based on the current trial data, the results indicate that both guided and self-managed iCBT are cost-effective with a willingness-to-pay threshold of well below €30,000/QALY. Additionally, self-managed iCBT is the most cost-effective strategy and has a lower impact on healthcare budgets.
Identifiants
pubmed: 31451978
doi: 10.1007/s10549-019-05410-w
pii: 10.1007/s10549-019-05410-w
pmc: PMC6817759
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
573-585Subventions
Organisme : KWF Kankerbestrijding
ID : 2014-6788
Références
Health Qual Life Outcomes. 2009 Mar 31;7:27
pubmed: 19335878
J Clin Oncol. 1996 May;14(5):1718-29
pubmed: 8622093
Acta Oncol. 2011 Feb;50(2):212-22
pubmed: 21231783
BMC Health Serv Res. 2013 Jun 15;13:217
pubmed: 23768141
Bull World Health Organ. 2015 Feb 1;93(2):118-24
pubmed: 25883405
Climacteric. 2006 Feb;9(1):49-58
pubmed: 16428125
Psychooncology. 2004 Nov;13(11):769-78
pubmed: 15386641
Pharmacoeconomics. 2000 May;17(5):445-59
pubmed: 10977387
Eur J Cancer. 2010 May;46(8):1382-91
pubmed: 20359886
Oncol Nurs Forum. 1999 Sep;26(8):1311-7
pubmed: 10497770
Br J Clin Psychol. 1995 Nov;34(4):589-99
pubmed: 8563666
J Clin Epidemiol. 1998 Nov;51(11):1055-68
pubmed: 9817123
Lancet. 2005 Sep 3-9;366(9488):818-24
pubmed: 16139656
Menopause. 2017 Jul;24(7):762-767
pubmed: 28195994
Menopause. 2014 Oct;21(10):1075-81
pubmed: 24618765
J Comp Eff Res. 2015 Sep;4(5):485-504
pubmed: 26490020
J Natl Cancer Inst. 2012 Mar 7;104(5):386-405
pubmed: 22271773
Qual Life Res. 2018 Aug;27(8):2077-2086
pubmed: 29740782
BMC Cancer. 2016 Nov 25;16(1):920
pubmed: 27887581
BMJ. 1996 Feb 17;312(7028):426-9
pubmed: 8601116
Psychooncology. 2016 Jan;25(1):51-7
pubmed: 26110652
J Clin Oncol. 2019 Apr 1;37(10):809-822
pubmed: 30763176
J Psychosom Obstet Gynaecol. 2017 Sep;38(3):226-235
pubmed: 27583832
JAMA. 2006 May 3;295(17):2057-71
pubmed: 16670414
Pharmacoeconomics. 2013 Jul;31(7):537-49
pubmed: 23620213
Menopause. 2012 Jul;19(7):749-59
pubmed: 22336748
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
N Engl J Med. 2001 Jun 28;344(26):1997-2008
pubmed: 11430330
Ann Pharmacother. 2013 Mar;47(3):380-7
pubmed: 23463742
Br J Psychiatry. 2005 Jan;186:11-7
pubmed: 15630118
J Clin Oncol. 2012 Nov 20;30(33):4124-33
pubmed: 23045575
J Cancer Surviv. 2015 Mar;9(1):126-35
pubmed: 25179578
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
Value Health. 2007 Sep-Oct;10(5):336-47
pubmed: 17888098
Breast Cancer Res Treat. 1999 May;55(2):189-99
pubmed: 10481946
Value Health. 2008 Dec;11(7):1131-43
pubmed: 18489495
Psychooncology. 2001 Nov-Dec;10(6):511-20
pubmed: 11747063
Pharmacoeconomics. 2002;20(7):443-54
pubmed: 12093300
Cancer. 2007 Mar 1;109(5):832-9
pubmed: 17243168
Value Health. 2012 Sep-Oct;15(6):812-20
pubmed: 22999130
J Clin Oncol. 2011 Oct 10;29(29):3862-8
pubmed: 21911720
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Qual Life Res. 2007 Aug;16(6):1073-81
pubmed: 17468943
Eur J Health Econ. 2018 Jul;19(6):861-870
pubmed: 28871490
Psychooncology. 2004 Mar;13(3):147-60
pubmed: 15022150
Lancet Oncol. 2012 Mar;13(3):309-18
pubmed: 22340966
Hematol Oncol Clin North Am. 2013 Aug;27(4):805-27, ix
pubmed: 23915746
Breast Cancer Res Treat. 2012 Jul;134(2):459-78
pubmed: 22689091
Int J Technol Assess Health Care. 2012 Apr;28(2):152-8
pubmed: 22559757
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614